J&J wins FDA OK for their nasal spray version of a party drug, now approved for treatment-resistant major depression
There it is.
Despite some serious clinical failures, the FDA has approved J&J’s new drug esketamine for major depression, which will now hit the market as Spravato.
An intranasal formulation of ketamine, a horse tranquilizer that is better known in party circles as Special K, the drug won a warm assessment by FDA insiders as well as an overwhelming vote in its favor by a panel of outside experts organized by the FDA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
